What we are working on

There is a tremendous volume of raw research data available in the public domain that compares gene expression in lupus patients with that of normal individuals.  Likewise, there is a vast amount of raw research data available that details gene abnormalities present in lupus patients.  RILITE seeks to employ a meta-analytic approach using the latest statistical methods to define lupus gene signatures, and to identify existing approved drugs that are candidates for repurposing for use in lupus treatment. Finally, by developing and applying unique machine learning algorithms, RILITE is seeking to develop methodology to predict disease activity, organ involvement and most appropriate therapies for individuals affected by SLE, and, thereby, advance the paradigm of the true precision medicine in the care of persons living with lupus.